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BACKGROUND: Cardiac troponin concentrations differ in
women and men, but how this influences risk predic-
tion and whether a sex-specific approach is required is
unclear. We evaluated whether sex influences the
predictive ability of cardiac troponin I and T for cardio-
vascular events in the general population.
METHODS: High-sensitivity cardiac troponin (hs-cTn) I
and T were measured in the Generation Scotland
Scottish Family Health Study of randomly selected vol-
unteers drawn from the general population between
2006 and 2011. Cox-regression models evaluated associ-
ations between hs-cTnI and hs-cTnT and the primary
outcome of cardiovascular death, myocardial infarction,
or stroke.
RESULTS: In 19 501 (58% women, mean age 47 years)
participants, the primary outcome occurred in 2.7%
(306/11 375) of women and 5.1% (411/8126) of men
during the median follow-up period of 7.9 (IQR,
7.1–9.2) years. Cardiac troponin I and T concentrations
were lower in women than men (P< 0.001 for both),
and both were more strongly associated with cardiovas-
cular events in women than men. For example, at a
hs-cTnI concentration of 10 ng/L, the hazard ratio rela-
tive to the limit of blank was 9.7 (95% CI 7.6–12.4)
and 5.6 (95% CI 4.7–6.6) for women and men, respec-
tively. The hazard ratio for hs-cTnT at a concentration
of 10 ng/L relative to the limit of blank was 3.7 (95%
CI 3.1–4.3) and 2.2 (95% CI 2.0–2.5) for women and
men, respectively.
CONCLUSIONS: Cardiac troponin concentrations differ
in women and men and are stronger predictors of car-
diovascular events in women. Sex-specific approaches
are required to provide equivalent risk prediction.
Introduction
Cardiovascular disease remains the main cause of death
worldwide with 17.6 million people dying each year (1,
2). The development of approaches to improve the pre-
diction and targeting of effective preventative therapies
for those at highest risk may help minimize the impact
of cardiovascular disease on the population. It is impor-
tant that these approaches are equitable for women and
men (2). In both primary and secondary care, guidelines
have been established in populations where men are
over represented and women seem to be disadvantaged
and receive fewer preventative treatments (3–5).
Cardiac biomarkers may provide an unbiased
aproach toward the prediction of cardiovascular events
in women and men. Increasingly, high-sensitivity car-
diac troponin is considered a useful marker of risk out-
with the setting of acute coronary syndromes to evaluate
asymptomatic individuals and guide therapeutic
approaches to prevent the onset of cardiovascular disease
(6–11). Recent major improvements in analytical per-
formance have greatly enhanced assay sensitivity, such
that with high-sensitivity assays we are now able to accu-
rately measure cardiac troponin concentrations in the
majority of healthy individuals (12). In a recent meta-
analysis of apparently healthy individuals, 43% of par-
ticipants with cardiac troponin concentrations in the
top third developed cardiovascular disease over the next
8 years (13).
It remains unclear in practice how best to harness
this prognostic information to guide the use of primary
and secondary prevention, and whether sex-specific tro-
ponin thresholds should be considered. The use of high-
sensitivity assays has identified important differences in
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troponin concentrations between men and women, with
the 99th centile upper reference limits used for diagnosis
of myocardial infarction up to 2-fold higher in men
(14). In our recent systematic review, we documented
that this observation is consistent for all troponin assays
across multiple cohorts from different ethnic back-
grounds (15). Furthermore, we recently demonstrated
in the Generation Scotland Scottish Family Health
Study, where both cardiac troponin I and T were mea-
sured in the same cohort, that differences in the 99th
centile between men and women exist for both bio-
markers across all age groups (16). Although several
studies have investigated cardiac troponins in relation to
cardiovascular outcomes in the general population (7,
11, 13, 17, 18), few have evaluated how sex influences
risk prediction, and it remains unclear whether a differ-
ent approach is required in women and men. Our aim
was to determine whether sex influences the predictive
ability of cardiac troponin I and T for cardiovascular
events in the general population.
Material and Methods
STUDY POPULATION
The Generation Scotland Scottish Family Health Study
is a well-phenotyped family-based cohort that enrolled
24 090 participants aged between 18 and 98 years and
has been described previously (7, 16, 19). Briefly, indi-
viduals between 35 and 65 years of age were identified
at random from participating general medical practices
in Scotland between 2006 and 2011. Participants were
asked to identify at least 1 first-degree relative who was
at least 18 years of age that would also enrol. For this
study, we excluded participants with missing cardiac tro-
ponin measurements. Study participants provided writ-
ten informed consent, including linkage to their medical
records. The study was conducted according to princi-
ples of the Declaration of Helsinki and was approved by
the National Health Service Tayside Committee on
Medical Research Ethics (REC Reference Number:
05/S1401/89). The study followed the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline.
CLINICAL CHARACTERISTICS
Participants completed a health questionnaire, and
had physical characteristics and clinical characteristics
measured according to a standardized protocol (19).
Past medical history, including a diagnosis of diabetes
mellitus, previous myocardial infarction or stroke, and
use of medications was self-reported. Family history of
cardiovascular disease was defined as a self-report of
parents or siblings having heart disease or stroke. Blood
samples were taken, according to a standard operating
procedure, and serum was prepared. Total cholesterol,
high-density lipoprotein cholesterol, and serum creati-
nine, were measured at the time of collection, and addi-
tional aliquots were stored at –80 C for future analyses.
The Scottish Index of Multiple Deprivation (2009)
scores were derived from participants’ postcodes: they
denote nationally compiled composite measures of
small-area deprivation (20).
CARDIAC TROPONIN MEASUREMENTS
Serum cardiac troponin I was measured on
ARCHITECT i1000SR high-sensitivity cardiac tropo-
nin I assay (Abbott Diagnostics) and cardiac troponin T
was measured on Cobas e411 high-sensitivity cardiac
troponin T (Roche Diagnostics) assay. During the con-
duct of this study, we participated in the National
External Quality Assurance Scheme (UKNEQAS) for
these biomarkers. Both assays were calibrated and qual-
ity controlled using the manufacturer’s reagents.
Coefficient of variations for cardiac troponin I were
6.2%, 6.0%, and 4.6% for the low, intermediate, and
high control, respectively. Coefficients of variation for
cardiac troponin T were 5.0% and 3.4% for the low
and high control, respectively. Cardiac troponin T has a
limit of blank (LoB) of 3 ng/L and limit of detection
(LoD) of 5 ng/L. Cardiac troponin I has a LoB of
1.2 ng/L and LoD of 1.9 ng/L (21).
CLINICAL OUTCOME
We used the Information Services Division National
Health Service record linkage for Scotland to collect
clinical outcome data until the end of September 2017.
Information on cause of death was obtained using the
National Health Service Central Register. Clinical out-
comes were classified using the 10th revision of the
International Classification of Diseases (ICD-10).
The primary outcome was a composite endpoint of
cardiovascular events including the following compo-
nent endpoints: (a) cardiovascular death (I00 to I99),
(b) myocardial infarction (I21, I22), and (c) stroke (I63,
I64, G45). Secondary outcomes were cardiovascular
death, noncardiovascular death, and all-cause death.
STATISTICAL ANALYSIS
Continuous variables are presented as mean (SD) or me-
dian (25th–75th percentile), as appropriate. Categorical
variables are presented as absolute numbers (%). For
continous analyses, troponin values below the LoB were
set to the LoB value divided by 2. The correlation
between cardiac troponin I and T was assessed by
Spearman correlation. Sex-specific incidence rates were
calculated per 1000 person-years for clinical outcomes.
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STATISTICAL LEARNING USING COX PROPORTIONAL HAZARD
REGRESSION MODELS
Unadjusted and adjusted multiple fractional polynomial
Cox proportional hazard regression analysis were con-
ducted to quantify the relationship between cardiac tro-
ponin as a continuous variable with the primary
outcome, stratified by sex. The multivariable model is
adjusted for age, total cholesterol, high-density lipopro-
tein cholesterol, systolic blood pressure, cigarettes
smoked per day, rheumatoid arthritis, diabetes mellitus,
Scottish Index of Multiple Deprivation score, family his-
tory of cardiovascular disease, use of blood pressure
medications, and use of cholesterol-lowering medica-
tions. Each continuous variable was chosen through
backward-stepwise selection of the best fractional poly-
nomial transformation. We created hazard ratio (HR)
plots for the primary outcome at 5 years of the unad-
justed and adjusted cardiac troponin I and T models for
women and men, and evaluated the HR relative to the
LoB. Due to the low proportion of missing covariates
(<6%) and the large number of available samples we
did not use imputation techniques, focusing on
complete case analysis instead. We constructed receiver
operating characteristic (ROC) curves and determined
the area under the curve (AUC) to assess discrimination
of cardiac troponin for predicting the primary outcome
at 5 years in women and men. Individuals with no
events by the 5-year mark were censored. Comparisons
between unpaired AUCs were tested according to the
DeLong method. In secondary analyses, we evaluated
the HR relative to the LoD, and we evaluated the
additional outcomes of cardiovascular death, noncardio-
vascular death, and all-cause death. All statistical analysis
was performed using R v.3.6.2.
Results
CLINICAL CHARACTERISTICS OF STUDY POPULATION
Our study population included 19 501 individuals
(58% women; Table 1) with a measured cardiac tropo-
nin I and T concentration available. On enrolment
women and men were at similar age (47 6 15 years),
Table 1. Baseline characteristics of entire study population and stratified by composite cardiovascular events.













Age (years) 47 (15) 47 (15) 47 (15) 46 (15) 65 (14) 62 (11)
Body mass index (kg/m2) 26.5 (5.6) 26.9 (4.5) 26.5 (5.6) 26.8 (4.4) 27.8 (5.6) 28.3 (4.8)
Systolic blood
pressure (mmHg)
128 (18) 136 (16) 128 (18) 136 (16) 141 (22) 142 (19)
Total cholesterol (mmol/L) 5.2 (1.1) 5.0 (1.1) 5.2 (1.1) 5.0 (1.06) 5.3 (1.3) 4.9 (1.2)
HDL cholesterol (mmol/L) 1.6 (0.4) 1.3 (0.3) 1.6 (0.4) 1.3 (0.3) 1.5 (0.4) 1.2 (0.4)
SIMD (score/10) 1.2 (0.7–2.4) 1.1 (0.7–2.1) 1.2 (0.7–2.4) 1.1 (0.7–2.1) 1.5 (0.8–2.9) 1.4 (0.8–2.6)
eGFR (mL/min/1.73 m2) 94 (17) 96 (17) 95 (17) 97 (17) 76 (20) 88 (25)
Cigarettes (per day) 2.3 (6.4) 2.7 (7.6) 2.2 (6.3) 2.6 (7.5) 4.3 (9.3) 4.9 (11.9)
Family history of CVD (yes) 4516 (40.4%) 2888 (36.5%) 4401 (40.5%) 2732 (36.4%) 115 (38.1%) 156 (38.5%)
Rheumatoid arthritis (yes) 213 (1.9%) 101 (1.2%) 195 (1.8%) 88 (1.1%) 18 (5.9%) 13 (3.2%)
Baseline CVD (yes) 369 (3.2%) 508 (6.3%) 302 (2.7%) 401 (5.2%) 67 (21.9%) 107 (26.0%)
Diabetes mellitus (yes) 256 (2.3%) 306 (3.8%) 228 (2.1%) 252 (3.3%) 28 (9.2%) 54 (13.1%)
Lipid-modifying
medication (yes)
604 (5.3%) 678 (8.3%) 548 (5.0%) 587 (7.6%) 56 (18.3%) 91 (22.1%)
Antihypertensive
medication (yes)
832 (7.3%) 742 (9.1%) 761 (6.9%) 646 (8.4%) 71 (23.2%) 96 (23.4%)
Cardiac troponin I (ng/L) 1.5 (1.2–2.5) 2.5 (1.6–4.0) 1.5 (1.2–2.4) 2.4 (1.6–3.9) 2.9 (1.8–5.9) 3.9 (2.3–7.3)
Cardiac troponin T (ng/L) 3.0 (3.0–4.8) 4.6 (3.0–7.5) 3.0 (3.0–4.7) 4.5 (3.0–7.3) 5.7 (3.0–10.5) 7.0 (3.8–12.2)
Detectable cardiac
troponin I (1.2 ng/L)
7523 (66.1%) 7056 (86.8%) 7252 (65.5%) 6663 (86.4%) 271 (88.6%) 393 (95.6%)
Detectable cardiac
troponin T (3.0 ng/L)
4826 (42.4%) 5569 (68.5%) 4610 (41.6%) 5238 (67.9%) 216 (70.6%) 331 (80.5%)
Categorical data are presented as n (%). Continuous variables are presented as mean (SD) or median (ranges, 25th–75th percentile), as appropriate. Abbreviatons: CVD, cardio-
vascular disease; eGFR, estimated glomerular filtration rate, HDL, high-density lipoprotein; SIMD, Scottish Index of Multiple Deprivation.
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but men were more likely to have risk factors, such as
hypertension or diabetes mellitus, or to have a history of
prior cardiovascular disease. Cardiac troponin concen-
trations were lower in women than men [cardiac tropo-
nin I, women 1.5 (1.2 to 2.5) ng/L versus men 2.5 (1.6
to 4.0) ng/L; cardiac troponin T, women 3.0 (3.0 to
4.8) ng/L versus men 4.6 (3.0 to 7.5) ng/L; P< 0.001
for both; Fig. 1]. The proportion of women and men
with cardiac troponin I concentrations above the LoD
was 66.1% (7523/11 375) and 86.8% (7056/8126),
and for cardiac troponin T it was 42.4% (4826/11 375)
and 68.5% (5569/8126). The correlation between car-
diac troponin I and T concentrations was lower in
women than men (r¼ 0.351, 95% CI 0.334 to 0.370
versus r¼ 0.446, 95% CI 0.428 to 0.463; P< 0.001).
CARDIAC TROPONINS AND CARDIOVASCULAR EVENTS IN
WOMEN AND MEN
The median follow-up period was 7.9 (7.1 to 9.2) years,
and a total number of 717 (3.7%) individuals experi-
enced a primary outcome event. In those participants
with an incident cardiovascular event (Table 1), women
were on average 3 years older than men (65 versus
62 years), but otherwise prior cardiovascular disease and
risk factors were similar. Women had fewer events than
men, with the primary outcome occurring in 306
(2.7%) women and 411 (5.1%) men during the follow-
up period (Table 2).
Based on our unadjusted and adjusted regression
models we illustrate the HR of a cardiovascular event at
5 years according to cardiac troponin I and troponin T
concentrations in men and women (Fig. 2). For estima-
tion of HRs, covariates were standardized for both
women and men to illustrate the relationship between
cardiac troponin and events in women and men with
similar characteristics. Both cardiac troponin I and T
concentrations were more strongly associated with the
primary outcome in women than men (Fig. 2, A and
C). For example, at a cardiac troponin I threshold of
10 ng/L, the unadjusted HR relative to the LoB was 9.7
(95% CI 7.6 to 12.4) for women compared to 5.6
(95% CI 4.7 to 6.6) for men. The unadjusted HR for a
cardiac troponin T threshold of 10 ng/L relative to LoB
was 3.7 (95% CI 3.1 to 4.3) for women and 2.2 (95%
CI 2.0 to 2.5) for men. Cardiac troponin I and T
thresholds of 2.1 ng/L and 6.0 ng/L, respectively, were
associated with a doubling of cardiovascular risk in
women. For men, a doubling of cardiovascular risk
required higher thresholds of 2.5 ng/L and 9.0 ng/L for
cardiac troponin I and T, respectively. Both cardiac
troponin I and T remained strongly associated with car-
diovascular events in women and men after adjustment
of other risk factors, but the divergence between women
and men was attenuated (Fig. 2, B and D).
Overall, cardiac troponin I and T concentrations
had a good discriminative ability to predict 5-year car-
diovascular risk (Fig. 3). For cardiac troponin I (AUC
0.73 in women versus AUC 0.68 in men, P¼ 0.080),
and for cardiac troponin T (AUC 0.72 in women versus
AUC 0.66 in men, P¼ 0.040) there was a trend toward
better discrimination in women than in men.
SECONDARY OUTCOMES
When using the LoD as reference value, we observed
that the differences in the association with cardiac tropo-
nin I and T on the primary outcome between women
and men were similar but attenuated (Fig. 1 in the
online Data Supplement). Consistent with our observa-
tions for the primary composite outcome, the incidence
of cardiovascular death was lower in women than men
(Table 2). In contrast, no difference was observed in the
incidence of noncardiovascular death between sexes.
Both cardiac troponin I and T were strongly associated
with cardiovascular death (online Supplemental Figs. 2
and 3, P< 0.001 for both) and all-cause death (online
Supplemental Figs. 4 and 5, P< 0.001 for both) in
women and men in fully adjusted models. Cardiac tro-
ponin I was not associated with noncardiovascular
death in either women (P¼ 0.597) or men (P¼ 0.364),
whereas cardiac troponin T was for both sexes
(P¼<0.001 in women, P¼ 0.004 in men; online
Supplemental Figs. 6 and 7).
Discussion
We have evaluated whether sex influences the prediction
of cardiac troponin I and T for cardiovascular events in
the general population. Our study has 3 main findings.
First, cardiac troponin I and T are independent predic-
tors of cardiovascular events in both women and men in
the general population. Second, cardiac troponin con-
centrations differ between women and men and are
stronger predictors of cardiovascular events in women.
Use of the same thresholds to guide risk of future
cardiovascular events in women and men would not
provide equivalent prediction. Third, differences in pre-
diction between women and men are largely explained
by the prevalence of cardiovascular risk factors and prior
disease, as the divergence between women and men was
attenuated after adjustment of other risk factors. These
findings highlight the importance of a sex-specific ap-
proach when using high-sensitivity cardiac troponin
testing in isolation for risk stratification and targeting
treatments to prevent cardiovascular disease. Ideally, car-
diac troponin would be used as a continuous measure in
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Fig. 1. Distribution of cardiac troponins in women and men. Violin plots of cardiac troponin I (A) and T (B) distribution, stratified
by sex (cardiac troponin I, women, 1.5 (1.2–2.5) ng/L versus men 2.5 (1.6–4.0) ng/L; cardiac troponin T, women 3.0 (3.0–4.8)
ng/L versus men 4.6 (3.0–7.5) ng/L, P< 0.001 for both; n¼ 11 375 for women, and n¼ 8126 for men).
Sex Differences in Cardiac Troponin I and T
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Table 2. Incidence rates of clinical outcomes in women and men.
Women (n¼11 375) Men (n¼8126)
Total events (%) Incidence rate Total events (%) Incidence rate
Composite cardiovascular
event
306 (2.7%) 3.3/1000 person-years 411 (5.1%) 6.3/1000 person-years
Myocardial infarction 81 (0.7%) 0.9/1000 person-years 178 (2.2%) 2.7/1000 person-years
Ischemic stroke 93 (0.8%) 1.6/1000 person-years 112 (1.4%) 2.3/1000 person-years
Cardiovascular death 128 (1.1%) 1.4/1000 person-years 138 (1.7%) 2.1/1000 person-years
Noncardiovascular death 206 (1.8%) 2.2/1000 person-years 168 (2.1%) 2.5/1000 person-years
All-cause death 334 (2.9%) 3.6/1000 person-years 306 (3.8%) 4.6/1000 person-years
Composite cardiovascular event¼myocardial infarction, ischemic stroke, or cardiovascular death.
Fig. 2. Hazard ratio plots for 5-year risk composite cardiovascular events. Troponin I: (A), unadjusted model; (B), adjusted model
and T: (C), unadjusted model; and (D), adjusted model concentrations in relation to composite cardiovascular events, stratified
by sex (referent¼ LoB value). The horizontal dashed line represents the doubling in risk of having a cardiovascular event within
5 years and the vertical dashed lines (red, women; gray, men) respresents the sex-specific thresholds of the 2-fold higher likeli-
hood experiencing a cardiovascular event, accordingly.
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a cardiovascular risk prediction tool that incorporates
sex and other clinical features.
Our study has several strengths. First, the
Generation Scotland Scottish Family Health Study
enrolled approximately 20 000 individuals and a high
proportion were women. Second, we were able to evalu-
ate both cardiac troponin I and T in almost the entire
cohort, permitting direct comparisons between markers
and ensuring our findings are both representative and
generalizable. Third, complete follow-up for almost
8 years ensured we had a sufficient number of cardiovas-
cular events to evaluate prediction in men and women
separately.
We found that cardiac troponins are strong inde-
pendent predictors of cardiovascular events and that in
their unadjusted, “raw” status, they are more strongly as-
sociated in women than men. This observation is in line
with the Atherosclerosis Risk in Communities (ARIC)
study, the Nord-Trøndelag Health Study (HUNT)
study and the Activity and Function in the Elderly in
Ulm (ActiFE) study, showing an interaction between
troponin and sex in relation to future cardiovascular
events across different ethnicities and age groups (18,
22, 23). Apart from differences in left ventricular mass
that could explain the lower troponin concentrations in
women than men (24–26), sex hormones may play a
role in the divergent cardiovascular risk prediction of
cardiac troponin concentrations for women and men
(27). Estrogens seems to have a cardioprotective effect
in premenopausal women, either directly or indirectly
(28–31). Differences in body fat distribution between
women and men may lead to a different cardiometabolic
risk profile (32), which could influence cardiac troponin
concentrations. Also, differences in the prevalence
of microvascular disease may play a role (33, 34).
However, in line with the ARIC study (22), ActiFE
study (23), the Prospective Investigation of the
Vasculature in Uppsala Seniors (PIVUS) study (35), the
Age, Gene/Environment Susceptibility-Reykjavik
(AGES-Reykjavik) study (36), and the Multi-Ethnic
study of Atherosclerosis (MESA) (37), we showed that
after adjustment of other risk factors the associations be-
tween cardiac troponins and outcome in women and
men became similar. This points out that the divergent
risk between sexes is at least partly explained by differen-
ces in cardiovascular risk profile. We determined
previously that age, diabetes, prior cardiovascular
disease, and lipid-lowering and antihypertensive medica-
tion use are important determinants for elevated cardiac
troponin concentrations (16), and adjusting for these
factors resulted in similar risk prediction for cardiac tro-
ponins in women and men.
What are the implications of these observed sex
differences? Women tend to be undertreated for cardio-
vascular risk (38), and cardiac troponin might be a tool
to bridge this imbalance. We believe that differences in
Fig. 3. Comparison of the discrimination of cardiac troponins for the prediction of the composite cardiovascular event in women
and men. Receiver-operating-curve for cardiac troponin I (A) and cardiac troponin T (B) to predict the composite cardiovascular
event at 5 years in women and men.
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prediction between women and men are largely
explained by the prevalence of cardiovascular risk factors
and prior disease, and therefore ideally cardiac troponin
would be used as a continuous measure in a risk predic-
tion tool that incorporates sex and other clinical fea-
tures. However, if cardiac troponin is used in isolation
to stratify patients into low- or high-risk groups for
screening purposes, it is essential that a sex-specific ap-
proach is adopted. We believe that future research
should focus on using cardiac troponin as a continuous
variable in a multivariable cardiovascular risk tool that
stratifies individuals based on their likelihood of cardio-
vascular disease. This would be in line with the develop-
ment of the use of troponins in the acute cardiac setting
(8), as the awareness has been raised that consideration
of cardiac troponin in a continuous fashion improves
risk assessment. Another major advantage of such an ap-
proach is that cardiac troponin could be corrected for
other relevant risk factors and that would eliminate the
problem of under- or overestimation for other impor-
tant subgroups apart from sex.
In contrast to the acute care setting, the general
population contains a high proportion of individuals
with cardiac troponin values below the LoD. As our
study was not designed to develop a risk prediction tool,
but rather to evaluate sex differences between troponins
in this setting, we have used cardiac troponins over their
entire concentration range. We therefore cannot exclude
that the imprecision profile of these assays in individuals
with very low cardiac troponin concentrations may have
affected the accuracy of our results. When using the
LoD rather than the LoB as the reference, differences
between women and men were less pronounced.
Women have lower troponin concentrations than men
and therefore a greater proportion of women have unde-
tectable cardiac troponin concentrations. Our analyses
suggest that discrimination in the modeling of future
cardiovascular events is partly dependent on being able
to identify those individuals who are very low risk with
the lowest cardiac troponin values. The clinical implica-
tions of this are important. For example, in the USA,
cardiac troponin values below the LoD are not reported
because of concerns about assay imprecision. While pre-
cision is greater in those with higher values and therefore
the user can be more confident in actioning the results
of those identified as higher risk, it is less clear that
based on current analytical precision (and reporting
requirements) we are fully harnessing the potential of
these tests to identify those who are lower risk. Those
developing clinical tools to guide primary prevention
approaches that incorporate cardiac troponin should be
aware that including troponin values below the LoD
may affect the accuracy of prediction and limit the fu-
ture application of these tools in practice.
Another important observation in our study is that
cardiac troponin T, but not cardiac troponin I predicts
noncardiovascular death in both women and men. This
extends our previous finding that cardiac troponin I has
a greater specificity for future cardiovascular risk (7, 16).
Although the underlying mechanism of this divergence
is not well understood and remains speculative, cardiac
troponin T elevations appear more strongly related to
chronic kidney and neuromuscular diseases (39, 40).
Furthermore, the curvilinear relationships between car-
diovascular risk and cardiac troponin I and T concentra-
tions differ. For cardiac troponin I, the risk increases in
the low troponin range, while for cardiac troponin T the
risk accelerates more at higher cardiac troponin values.
This divergence may reflect differences in assay precision
at very low concentrations and could be an important
consideration for the development and implementation
of risk prediction tools incorporating troponin, as model
performance is likely to be very sensitive to assay choice.
Several limitations merit attention. First, no cardiac
imaging data were available and studying the possible
structural microvascular cardiac differences between
women and men in relation to troponin and outcome
was not possible, although this is of secondary value as
we have incident cardiovascular outcomes. Second,
most of the Generation Scotland Family Health Study
participants are Caucasian and generalizing our findings
to other ethnic groups should be done with caution.
Third, although high-sensitivity testing was used, still a
high proportion of individuals had undetectable cardiac
troponin concentrations, particularly for cardiac tropo-
nin T and particularly in women. Imprecision in those
with very low cardiac troponin concentrations might
have influenced the accuracy of our model estimates.
Finally, cardiac troponin I was only measured using one
manufacturer’s assay, which precludes the direct extrap-
olation of our findings to other cardiac troponin I
assays.
In conclusion, cardiac troponin I and T are inde-
pendent predictors of cardiovascular events in both
women and men in the general population. Cardiac tro-
ponin concentrations differ in women and men and are
stronger predictors of cardiovascular events in women.
Sex-specific approaches are required to provide equiva-
lent risk prediction when using high-sensitivity cardiac
troponin testing in isolation for risk prediction and the
prevention of cardiovascular disease. Ideally, cardiac tro-
ponin would be used as a continuous measure in a car-
diovascular risk prediction tool that incorporates sex and
other clinical features.
Supplemental Material
Supplemental material is available at Clinical Chemistry
online
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